Friday, May 31, 2019
electroCore (ECOR)
Can the Reduced Cash Burn Calm Ragged Nerves?
Electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Concern around the high cash burn is lowered. electroCore implemented a cost reduction and deployment plan reducing the cash burn to $2.3 million from $4 million per month, effective by June 2019. We view extension of the cash runaway as a positive road map for the company, but we believe the stock will remain under pressure until the company shows a solid revenue ramp-up.
- Basis of the cost reduction plan. The cost reduction was endowed by i) reducing work force to 55 positions from 91 – eliminating sales, medical affairs personnel, ii) abolishing cash compensation of board servicing by independent directors, iii) voluntary acceptance of stock compensation in lieu of cash compensation by Chief Executive Officer Francis Amato and iv) postponing current clinical operations – to be determined following the company’s board meeting on June.
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.